Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus

BMC Pediatrics

Reinhard W Holl⁵  Marguerite Honer¹  Kai Kronfeld²  Barouk M Assael⁴  Dominique Hubert³  Manfred Ballmann⁶ 

[1] Mukoviszidose Institut gGmbH, Bonn, Germany;Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre, Mainz, Germany;Service de Pneumologie, APHP Hôpital Cochin, Paris, France;Ospedale Civile Maggiore, Verona, Italy;University of Ulm, Institute of Epidemiology and Medical Biometry, Ulm, Germany;Department Paediatric Pulmonology, Paediatric clinic at St Josef Hospital, Ruhr University Bochum, Alexandrinen Strasse 5, Bochum 44197, Germany

关键词: Clinical trial;    HbA1c;    Insulin;    Repaglinide;    Inborn;    Genetic diseases;    Lung diseases;    Diabetes mellitus;    Cystic fibrosis;   

Others  :  1138962
DOI  :  10.1186/1471-2431-14-70

 received in 2014-01-15, accepted in 2014-03-03,  发布年份 2014

【 摘 要 】

Background

Diabetes mellitus may be present in patients with cystic fibrosis starting in the second decade of life. The prevalence increases rapidly with increasing age. As life-expectancy increases in cystic fibrosis, cystic fibrosis related diabetes will be diagnosed more frequently in the future.

Up to date, no data are available to answer the question if cystic fibrosis related diabetes should always initially be treated by insulin therapy. Missing data regarding oral antidiabetic treatment of newly diagnosed cystic fibrosis related diabetes are an important reason to recommend insulin treatment. Several centres report the successful management of cystic fibrosis related diabetes using oral anti-diabetic drugs at least for some years. Oral therapies would be less invasive for a patient group which is highly traumatized by a very demanding therapy. Based on an initiative of the German Mukoviszidosis-Foundation, the present study tries to answer the question, whether oral therapy with repaglinide is as effective as insulin therapy in cystic fibrosis patients with early diagnosed diabetes mellitus.

Methods/Design

In all cystic fibrosis patients with an age of 10 years or older, an oral glucose tolerance test is recommended. The result of this test is classified according to the WHO cut off values. It is required to have two diabetes positive oral glucose tolerance tests for the diagnosis of diabetes mellitus.

This study is a multi-national, multicentre, open labelled, randomized and prospective controlled parallel group’s trial, with 24 months treatment.

The primary objective of this trial is to compare the glycaemic control of oral therapy with Repaglinide with insulin injections in patients with cystic fibrosis related diabetes after 2 years of treatment.

The trial should include 74 subjects showing cystic fibrosis related diabetes newly diagnosed by oral glucose tolerance test during annual screening for cystic fibrosis related diabetes.

Patients are randomised by central fax randomisation.

Primary endpoint is mean HbA1c after 24 months of treatment. Secondary endpoints are change in FEV1% predicted and change in BMI-Z-score.

Discussion

There is only one prospective study comparing oral antidiabetic drugs to insulin in the treatment of CFRD without fasting hyperglycaemia. The results regarding BMI after 6 months and 12 months showed an improvement for the insulin treated patients and were inconsistent for those treated with repaglinide. HbA1c and lung function (FEV1%pred) were unchanged for either group. The authors compared the changes -12 months to baseline and baseline to +12 months separately for each group. Therefore a direct comparison of the effect of repaglinide versus insulin on BMI, HbA1c and FEV1%pred was not presented. According to our protocol, we will directly compare treatment effects (HbA1c, BMI, FEV1%pred) in between both groups. The actual Cochrane report regarding “Insulin and oral agents for managing CFRD” stated that further studies are needed to establish whether there is clear benefit for hypoglycemic agents. We expect that the results of our study will help to address this clinical need.

Trial registration

ClinicalTrials.gov Identifier: NCT00662714

【 授权许可】

   
2014 Ballmann et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kelly A, Moran A: Update on cystic fibrosis-related diabetes. J Cyst Fibros 2013, 12(4):318-331.
• [2]Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B: Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010, 33(12):2697-2708.
• [3]Onady GM, Stolfi A: Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2013., 7CD004730
• [4]Fischman D, Nookala VK: Cystic fibrosis-related diabetes mellitus: etiology, evaluation, and management. Endocr Pract 2008, 14(9):1169-1179.
• [5]Onady GM, Stolfi A: Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2005., 3CD004730
• [6]Mueller-Brandes C, Holl RW, Nastoll M, Ballmann M: New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis. Eur Respir J 2005, 25(4):715-717.
• [7]Rosenecker J, Eichler I, Barmeier H, von der Hardt H: Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents. Pediatr Pulmonol 2001, 32(5):351-355.
• [8]Onady GM, Langdon LJ: Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC Endocr Disord 2006, 6:4. BioMed Central Full Text
• [9]Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, Tullis E, Liou TG, Allen H: Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009, 32(10):1783-1788.
• [10]Bretzel RG: Diagnostik und Therapie. In Diabetologie in Klinik und Praxis. 6th edition. Edited by Haering HU, Gallwitz B, Mueller-Wieland D, Usadel K-H, Mehnert H. Stuttgart, New York: Thieme; 2011:192-211.
• [11]Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C: Glucose tolerance in patients with cystic fibrosis: five year prospective study. Bmj 1995, 311(7006):655-659.
• [12]Ziaian T, Sawyer MG, Reynolds KE, Carbone JA, Clark JJ, Baghurst PA, Couper JJ, Kennedy D, Martin AJ, Staugas RE, French DJ: Treatment burden and health-related quality of life of children with diabetes, cystic fibrosis and asthma. J Paediatr Child Health 2006, 42(10):596-600.
• [13]Sawicki GS, Sellers DE, Robinson WM: High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009, 8(2):91-96.
• [14]Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M: Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. J Cyst Fibros 2014, 13(1):80-85.